University of Salerno Report issue

Academic/Hospital Phase 3
Founded: Fisciano Italy (1968)

Organization Overview

First Clinical Trial
2012
NCT02342366
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Antonella Santonicola | Carolina Ciacci | Maria Teresa Pellecchia | Roberto Erro | University of Salerno

Active Ingredients

Drugs in Phase 3 Trials (1)

irbesartan (avapro) (1 trial)

Drugs in Other Trials (3)

lactobacillus casei (1 trial)

sodium bicarbonate (1 trial)

sodium oxybate (xyrem) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Sepsis (Phase 3)

Toxemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4